CpG island methylator phenotype and its relationship with prognosis in adult acute leukemia patients

Hematology

Volumn 19, Issue 6, 2014, Pages 329-337

  Fu, Hai Ying ^a   Wu, Dan Sen ^a   Zhou, Hua Rong ^a   Shen, Jian Zhen ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Adult acute leukemia; CpG Islands Methylator Phenotype (CIMP); DNA methylation; Progression

Indexed keywords

ADOLESCENT; ADULT; AGED; CPG ISLAND; DNA METHYLATION; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CPG ISLANDS; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; YOUNG ADULT;

EID: 84905189646     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845413Y.0000000137     Document Type: Article

References (53)

1. Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR. Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer 2013;119:2720-2727.
2. Abdel-Wahab O, Levine RL. Recent advances in the treatment of acute myeloid leukemia. F1000 Med Rep. 2010;2:55.
3. Dunphy CH. Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications. Arch Pathol Lab Med. 2006;130:483-520.
4. Mrozek K, Harper DP, Aplan PD. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23:991-1010.
5. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051-1062.
6. Fizzotti M, Cimino G, Pisegna S, Alimena G, Quartarone C, Mandelli F, et al. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lympho-blastic leukemia and association with adverse prognostic features. Blood 1995;85:2685-2690.
7. Hebert J, Cayuela JM, Berkeley J, Sigaux F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T-but not from B-cell lineage acute lymphoblastic leukemias. Blood 1994;84:4038-4044.
8. Kees UR, Burton PR, Lu C, Baker DL. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood 1997;89: 4161-4166.
9. Frohling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol. 2005;23:6285-6295.
10. Corn PG, Smith BD, Ruckdeschel ES, Douglas D, Baylin SB, Herman JG E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia. Clin Cancer Res. 2000;6: 4243-4248.
11. Feng M, Huang B, Du Z, Xu X, Chen Z. DLC-1 as a modulator of proliferation, apoptosis and migration in Burkitt's lymphoma cells. Mol Biol Rep. 2011;38:1915-1920.
12. Fu HY, Shen JZ, Wu Y, Shen SF, Zhou HR, Fan LP. Arsenic tri-oxide inhibits DNA methyltransferase and restores expression of methylation-silenced CDKN2B/CDKN2A genes in human hematologic malignant cells. Oncol Rep. 2010;24:335-343.
13. Kroeger H, Jelinek J, Estecio MR, He R, Kondo K, Chung W, et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 2008;112:1366-1373.
14. Shen JZ, Xu CB, Fu HY, Wu DS, Zhou HR, Fan LP. Methylation of secreted frizzled related protein gene in acute leukemia patients in China. Asian Pac J Cancer Prev. 2011;12: 2617-2621.
15. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010; 28:605-613.
16. Alvarez S, Suela J, Valencia A, Fernández A, Wunderlich M, Agirre X, et al. DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS ONE 2010;5:e12197.
17. Guo SX, Taki T, Ohnishi H, Piao HY, Tabuchi K, Bessho F, et al. Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia. Leuk Res. 2000;24:39-46.
18. Kraszewska MD, Dawidowska M, Larmonie NS, Kosmalska M, Sedek L, Szczepaniak M, et al. DNA methylation pattern is altered in childhood T-cell acute lymphoblastic leukemia patients as compared with normal thymic subsets: insights into CpG island methylator phenotype in T-ALL. Leukemia 2012; 26:367-371.
19. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Garate L, et al. Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. Leukemia 2006;20:1445-1448.
20. Yagi K, Akagi K, Hayashi H, Nagae G, Tsuji S, Isagawa T, et al. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res. 2010;16:21-33.
21. Agrawal S, Unterberg M, Koschmieder S, zur Stadt U, Brunnberg U, Verbeek W, et al. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res. 2007;67:1370-1377.
22. Wakabayashi T, Natsume A, Hatano H, Fujii M, Shimato S, Ito M, et al. p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. Neurosurgery 2009;64:455-461.
23. Zhao Y, Wang QS, Dou LP, Bo J, Li HH, Jing Y, et al. Methylation of Id4 gene promoter in acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007;15:1156-1160.
24. Tan SH, Ida H, Lau QC, Goh BC, Chieng WS, Loh M, et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep. 2007;18:1225-1230.
25. Kajabova V, Smolkova B, Zmetakova I, Sebova K, Krivulcik T, Bella V, et al. RASSF1A promoter methylation levels positively correlate with estrogen receptor expression in breast cancer patients. Transl Oncol. 2013;6:297-304.
26. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, et al. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res. 2001;61:4556-4560.
27. Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562-569.
28. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4:988-993.
29. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-8686.
30. Oue N, Mitani Y, Motoshita J, Matsumura S, Yoshida K, Kuniyasu H, et al. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer 2006;106:1250-1259.
31. Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y, et al. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res. 2005;65: 828-834.
32. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-96.
33. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 2001;61:3410-3418.
34. Sato H, Oka T, Shinnou Y, Kondo T, Washio K, Takano M, et al. Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lym-phoma. Am J Pathol. 2010;176:402-415.
35. Lacayo NJ, DiMartino JF, Wei MC, Dahl GV. CpG island methylator phenotype and childhood leukemia. Clin Cancer Res. 2006;12:4787-4789.
36. Zhang ZN. Criteria for diagnosis and determing therapeutic efficacy of hematological diseases. Beijing: Science Press; 2007.
37. Lee AY, He B, You L, Dadfarmay S, Xu Z, Mazieres J, et al. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 2004;23: 6672-6676.
38. Lin DJ, Fan RF, Liu XF. Significance of DNA methylation status of runx3 gene promoter region in acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008;16:263-266.
39. Mori S, Ito G, Usami N, Yoshioka H, Ueda Y, Kodama Y, et al. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Cancer 2004;100:1673-1682.
40. Roman-Gomez J, Castillejo JA, Jimenez A, Cervantes F, Boque C, Hermosin L, et al. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. J Clin Oncol. 2003; 21:1472-1479.
41. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Agirre X, Barrios M, Navarro G, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 2004;104:2492-2498.
42. Shi H, Guo J, Duff DJ, Rahmatpanah F, Chitima-Matsiga R, Al-Kuhlani M, et al. Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. Carcinogenesis 2007;28:60-70.
43. Zhao Y, Jing Y, Bo J, Wang SH, Wang QS, Li HH, et al. Significance of id4 gene promoter methylation detection in lym-phoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008;16:322-324.
44. Hutchinson L. Hematology. DNA methylation predicts survival in adult AML. Nat Rev Clin Oncol. 2010;7(4):181-183.
45. Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH, Kim JS. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol. 2003;163:1551-1556.
46. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Cancer genome atlas research network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17: 510-522.
47. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17(5):510-522.
48. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 1998;58:2196-2199.
49. Liao YC, Lo SH. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int J Biochem Cell Biol. 2008;40: 843-847.
50. Pike BL, Greiner TC, Wang X, Weisenburger DD, Hsu YH, Renaud G, et al. DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia 2008;22:1035-1043.
51. Taylor KH, Pena-Hernandez KE, Davis JW, Arthur GL, Duff DJ, Shi H, et al. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res. 2007;67:2617-2625.
52. Ying J, Li H, Murray P, Gao Z, Chen YW, Wang Y, et al. Tumor-specific methylation of the 8p22 tumor suppressor gene DLC1 is an epigenetic biomarker for Hodgkin, nasal NK/T-cell and other types of lymphomas. Epigenetics 2007;2:15-21.
53. Ullmannova-Benson V, Guan M, Zhou X, Tripathi V, Yang XY, Zimonjic DB, et al. DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. Leukemia 2009;23:383-390.